Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with daratumumab-len-dex

被引：0
|
作者：
Giannotta, Claudia [1 ]
Ziccheddu, Bachisio [2 ]
D'Agostino, Mattia [3 ,4 ]
Bertuglia, Giuseppe [5 ]
Saraci, Elona [5 ]
Oliva, Stefania [5 ]
Bolli, Niccolo' [6 ]
Landgren, Ola [7 ]
Bruno, Benedetto [3 ,4 ]
Boccadoro, Mario [8 ]
Maura, Francesco [7 ]
Massaia, Massimo [1 ]
Larocca, Alessandra [5 ]
机构：
[1] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr Guido Tarone, Lab Blood Tumor Immunol, Turin, Italy
[2] Univ Miami, Coral Gables, FL 33124 USA
[3] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[4] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[5] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Ematol U, Myeloma Unit, Turin, Italy
[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Milan, Italy
[7] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Cattedra Ematol, Hematol Div, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-392
引用
收藏
页码：S256 / S257
页数：2
相关论文
共 50 条
  • [21] Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma
    Chehab, Sarah
    Panjic, Elyse Hall
    Gleason, Charise
    Lonial, Sagar
    Nooka, Ajay K.
    FUTURE ONCOLOGY, 2018, 14 (30) : 3111 - 3121
  • [22] Safety of rapid daratumumab infusion in relapsed and refractory multiple myeloma
    Antonioli, Elisabetta
    Attardi, Enrico
    Staderini, Michela
    Nozzoli, Chiara
    Buzzichelli, Alessandra
    Messeri, Maria
    Bosi, Alberto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E141 - E141
  • [23] SAFETY OF RAPID DARATUMUMAB INFUSION IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Attardi, E.
    Antonioli, E.
    Staderini, M.
    Messeri, M.
    Buzzichelli, A.
    Nencini, V.
    Fani, A.
    Bosi, A.
    HAEMATOLOGICA, 2019, 104 : 65 - 66
  • [24] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [25] Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma
    Chen, Pingping
    Ma, Jiexian
    Qian, Wensi
    Wu, Min
    Shen, Lin
    Xie, Yanhui
    MINERVA PEDIATRICS, 2024, 76 (01): : 121 - 123
  • [26] Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma
    Yoon, Sung-Soo
    Byun, Ja Min
    Park, Hyunkyung
    Lee, Ji Yun
    Koh, Youngil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E155 - E156
  • [27] Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
    Bapatla, Anusha
    Kaul, Arunima
    Dhalla, Paramvijay Singh
    Armenta-Quiroga, Ana S.
    Khalid, Raheela
    Garcia, Jian
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [28] High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
    Adams, Homer C., III
    Stevenaert, Frederik
    Krejcik, Jakub
    Van der Borght, Koen
    Smets, Tina
    Bald, Jaime
    Abraham, Yann
    Ceulemans, Hugo
    Chiu, Christopher
    Vanhoof, Greet
    Usmani, Saad Z.
    Plesner, Torben
    Lonial, Sagar
    Nijhof, Inger
    Lokhorst, Henk M.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    Sasser, Amy Kate
    Casneuf, Tineke
    CYTOMETRY PART A, 2019, 95A (03) : 279 - 289
  • [29] Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma
    Cho, Hee Jeong
    Jo, Jae-Cheol
    Lee, Yoo Jin
    Lee, Myung Won
    Kim, Do Young
    Shin, Ho Jin
    Im, Sung Nam
    Lee, Ji Hyun
    Bae, Sung Hwa
    Do, Young Rok
    Lee, Won Sik
    Kim, Min Kyung
    Jung, Jina
    Lee, Jung Min
    Kim, Ju-Hyung
    Baek, Dong Won
    Sohn, Sang-Kyun
    Moon, Joon Ho
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (02): : 238 - +
  • [30] ASSAY INTERFERENCE AND BLOOD TRANSFUSION SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH DARATUMUMAB.
    Catamero, Donna
    Morgan, Gillian
    Khan, Imran
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 83 - 83
12345